| human | Q5 |
| P5463 | AE member ID | Tropé_Claes_Goran |
| P2671 | Google Knowledge Graph ID | /g/1yfp3pm9l |
| P166 | award received | King Olav V's Prize for Cancer Research | Q11981638 |
| P27 | country of citizenship | Sweden | Q34 |
| P108 | employer | University of Oslo | Q486156 |
| P734 | family name | Tropé | Q47090451 |
| Tropé | Q47090451 | ||
| Tropé | Q47090451 | ||
| P735 | given name | Claes | Q19818179 |
| Claes | Q19818179 | ||
| Göran | Q1559427 | ||
| Göran | Q1559427 | ||
| P463 | member of | Academia Europaea | Q337234 |
| P106 | occupation | physician | Q39631 |
| professor | Q121594 | ||
| P21 | sex or gender | male | Q6581097 |
| Q68673518 | A 16-year-old girl with invasive carcinoma of the vulva |
| Q48004215 | A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing |
| Q40667322 | A Phase II Study of Combined Adriamycin, L-PAM, and Methotrexate with Citrovorum Factor Rescue in Advanced Ovarian Carcinomas |
| Q46904412 | A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach |
| Q79398411 | A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports |
| Q43960904 | A new prognostic instrument. Histopathological multi-factor analysis of invasive squamous cell carcinoma of the cervix uteri |
| Q37106836 | A novel truncated form of HMGA2 in tumors of the ovaries |
| Q39514946 | A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer |
| Q39520045 | A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer |
| Q70655396 | A phase II study of Cis-platinum for recurrent corpus cancer |
| Q33495084 | A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma |
| Q68801482 | A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas |
| Q72625490 | A phase II study of prednimustine in advanced ovarian cancer |
| Q40570624 | A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. |
| Q72443905 | A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma |
| Q40852028 | A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities |
| Q39731957 | A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection |
| Q69182532 | A serious ovarian cystadenocarcinoma metastatic to both eyes |
| Q35574875 | A systematic overview of radiation therapy effects in cervical cancer (cervix uteri). |
| Q35574882 | A systematic overview of radiation therapy effects in ovarian cancer |
| Q35574878 | A systematic overview of radiation therapy effects in uterine cancer (corpus uteri). |
| Q88072881 | APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival |
| Q90387906 | Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma |
| Q54538169 | Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. |
| Q33290241 | Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature |
| Q39241077 | Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix: a third look |
| Q37017000 | Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer |
| Q71653533 | Age and prognosis in stage Ib squamous cell carcinoma of the uterine cervix |
| Q43513556 | Aldehyde dehydrogenase-1 predicts favorable prognosis in patients with vulvar squamous cell carcinoma |
| Q24536023 | Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma |
| Q74087847 | An evaluation of prognostic factors in uterine carcinosarcoma |
| Q72836815 | Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse |
| Q40918718 | Antineoplastic-drug effect evaluated with a new X-ray stereophotographic measurement of the tumour volume |
| Q40798661 | Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors |
| Q84776479 | Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes |
| Q67021532 | Arrest of growth of ovarian tumor by tranexamic acid |
| Q85327489 | Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance |
| Q36696220 | BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study |
| Q54212025 | BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. |
| Q42435945 | Basal cell carcinoma of the vulva |
| Q72619868 | Bleomycin alone or combined with mitomycin C in treatment of advanced or recurrent squamous cell carcinoma of the vulva |
| Q72670921 | Bleomycin combined with mitomycin C in recurrent cervix cancer |
| Q41111975 | Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look |
| Q33476066 | Bleomycin-mitomycin C in advanced carcinoma of the cervix. A third look |
| Q37982899 | Borderline ovarian tumours |
| Q43872343 | CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer |
| Q68198856 | CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma |
| Q34473048 | CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients |
| Q35108670 | CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma |
| Q36603653 | CO2 laser for the treatment of invasive vulvar and vaginal cancer |
| Q44261967 | Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases |
| Q68057845 | Cancer of the endometrium: value of MR imaging in determining depth of invasion into the myometrium |
| Q73028627 | Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions |
| Q77362156 | Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up |
| Q67240810 | Carcinoma of the Ovary in Stage III: Effects of Postoperative Chemotherapy, Radiation Therapy and Repeat Laparotomy |
| Q64049447 | Carcinoma of the fallopian tube |
| Q67263215 | Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy |
| Q94040642 | Caveolin-1 expression in ovarian carcinoma is MDR1 independent |
| Q70462998 | Cell cycle perturbations in heterotransplanted squamous-cell carcinoma of the head and neck after mitomycin C and cisplatin treatment |
| Q53604461 | Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases. |
| Q64889488 | Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. |
| Q52561139 | Changes in Histology and Cell Kinetics During the Growth Course of Xenografted Squamous Cell Carcinoma |
| Q69289548 | Changes in tumor morphology in one human endometrial carcinosarcoma heterotransplanted into nude mice |
| Q40648804 | Chemotherapy of metastatic carcinoma of the breast. A 4-drug regimen |
| Q87452268 | Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted |
| Q77666706 | Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis |
| Q36431436 | Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells |
| Q71447475 | Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up |
| Q43454152 | Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance |
| Q45811963 | Claudin upregulation in ovarian carcinoma effusions is associated with poor survival |
| Q71659233 | Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern |
| Q34321441 | Clear-cell and papillary serous cancer: treatment options |
| Q58270036 | Clinical Stage I Carcinoma of the Cervix |
| Q35575176 | Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. |
| Q73181602 | Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer |
| Q52517527 | Clinical stage I carcinoma of the cervix. Value of MR imaging in determining invasion into the parametrium. |
| Q41882838 | Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay |
| Q68110858 | Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer |
| Q67503417 | Comparison of HPV detection in parallel biopsies and cervical scrapes by PCR |
| Q69158904 | Comparison of estrogen receptor enzyme immunoassay and a radioligand binding assay (isoelectric focusing) in adenocarcinoma of the uterine body |
| Q80479062 | Consistent numerical chromosome aberrations in thecofibromas of the ovary |
| Q51903504 | Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? |
| Q34151267 | Controversies in surgical management of advanced ovarian cancer (stage III-IV). |
| Q44326108 | Controversies in surgical treatment of advanced ovarian cancer |
| Q43156767 | Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer |
| Q70535579 | Correlation between estradiol-17 beta and progesterone cytosol receptor concentration, histologic differentiation and 3H-thymidine incorporation in endometrial carcinoma |
| Q73255157 | Critical soft tissues of the female pelvis: serial MR imaging before, during, and after radiation therapy |
| Q81748114 | Cyclins D1, D3, E, and A in vulvar carcinoma patients |
| Q73886951 | DNA copy number changes in malignant ovarian germ cell tumors |
| Q70217404 | DNA examinations in gynecological cancer and breast cancer |
| Q35695327 | DNA flow cytometry as a new prognostic factor in ovarian malignancies. A review. |
| Q21245727 | DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets |
| Q71973990 | DNA ploidy and expression of p53 and C-erbB-2 in extramammary Paget's disease of the vulva |
| Q37794750 | DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens |
| Q72401862 | DNA ploidy in epithelial ovarian cancer: a new independent prognostic factor? |
| Q36203480 | DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium |
| Q74572526 | DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary |
| Q81557844 | Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma |
| Q37298324 | Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma |
| Q41769134 | Detection of genital papillomavirus types by polymerase chain reaction using common primers |
| Q37629779 | Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". |
| Q34336818 | Diagnosis and treatment of sarcoma of the uterus. A review |
| Q73605103 | Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy |
| Q46086272 | Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice |
| Q69637897 | Doxorubicin-cisplatin combination chemotherapy for recurrent carcinoma of the cervix |
| Q73161846 | Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group |
| Q52891983 | Early detection of familial ovarian cancer. |
| Q54232915 | Effect of estradiol on tumor growth, cell kinetics and p53 oncoprotein expression in human endometrial adenocarcinoma heterotransplanted into nude mice. |
| Q44955068 | Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma |
| Q73469329 | Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients |
| Q35265256 | Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors |
| Q35918875 | Endometrial cancer: the management of high-risk disease |
| Q73392443 | Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer |
| Q41314826 | Epithelial ovarian carcinoma |
| Q35971814 | Epithelial-mesenchymal transition in ovarian carcinoma |
| Q50957685 | Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors. |
| Q69792952 | Estrogen receptor content in nuclear pellet from adenocarcinoma corporis uteri biopsies |
| Q77212640 | Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome |
| Q89378776 | Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro |
| Q43257214 | Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters |
| Q43748035 | Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study |
| Q74572484 | Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary |
| Q53366401 | Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. |
| Q71104436 | Evaluation of the prognostic significance of nm23/NDP kinase protein expression in cervical carcinoma: an immunohistochemical study |
| Q38985333 | Exosome-derived miRNAs and ovarian carcinoma progression |
| Q73501589 | Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma |
| Q84266227 | Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma |
| Q40671439 | Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma |
| Q50134593 | Expression and clinical role of long non-coding RNA in high-grade serous carcinoma |
| Q77161657 | Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients |
| Q49719798 | Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma |
| Q73581136 | Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications |
| Q35304430 | Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis |
| Q54577777 | Expression of E-cadherin transcriptional regulators in ovarian carcinoma. |
| Q73190404 | Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer |
| Q74630621 | Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications |
| Q81511198 | Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation |
| Q73731088 | Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions |
| Q34666213 | Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma |
| Q73268714 | Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis |
| Q36502762 | Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: A clinicopathological analysis of 238 patients |
| Q37709081 | Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva |
| Q36131154 | Ezrin Is Associated with Disease Progression in Ovarian Carcinoma |
| Q53092504 | Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. |
| Q86297469 | Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era" |
| Q34352545 | Fertility preservation in gynecologic cancer |
| Q69438469 | Flow cytometric DNA analysis of normal and cancerous human endometrium and cytological-histopathological correlations |
| Q74566544 | Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method |
| Q72313719 | Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma |
| Q61051658 | Genetic alterations of the TP53 gene, p53 protein expression and hpv infection in primary cervical carcinomas |
| Q86103494 | Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva |
| Q33728834 | Genomic aberrations in borderline ovarian tumors |
| Q38830107 | Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression |
| Q33913984 | Genomic profile of ovarian carcinomas |
| Q64986498 | Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis. |
| Q70387574 | Giant condyloma acuminatum with focal malignant degeneration |
| Q47616090 | Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma |
| Q33693203 | Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation |
| Q83782854 | Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications |
| Q81120938 | HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma |
| Q35605755 | HMGA2 expression pattern and TERT mutations in tumors of the vulva |
| Q83811112 | HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases |
| Q36203121 | HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer |
| Q41071376 | HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival |
| Q34639376 | Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991. |
| Q44286102 | Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions |
| Q67526074 | Heterogeneity in in vitro response to progesterone and melphalan of mammary tumours induced in the rat by 7,12-DMBA |
| Q67006287 | Heterogeneous Response of Disseminated Human Ovarian Cancers to Cytostatics in Vitro |
| Q58164918 | Heterotransplantation of Human Head and Neck Tumours Into Nude Mice |
| Q41907826 | Heterotransplantation of human malignant endometrial tumors into nude mice |
| Q70360993 | Heterotransplantation of two human tumours in athymic mice and asplenic-athymic mice |
| Q45050356 | Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer |
| Q31119438 | High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients |
| Q72667378 | High-dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma |
| Q36649758 | Histologic pattern and growth in two human testis cancers before and after transplantation to nude mice |
| Q43414490 | Histological grading and treatment failures in carcinoma of the uterine body. |
| Q44213794 | Histopathological characteristics predictive for growth of squamous cell carcinomas of the head and neck heterotransplanted to nude mice |
| Q67314421 | Human Ovarian Tumours Heterotransplanted to “Nude” Mice |
| Q71012839 | Human malignant melanoma heterotransplanted to nude mice |
| Q45767317 | Human papilloma virus has no prognostic significance in cervical carcinoma |
| Q72384090 | Human papillomavirus infection in Norwegian women with cervical cancer |
| Q36396500 | Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure |
| Q36641944 | Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis |
| Q52597231 | Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas. |
| Q83855411 | Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas |
| Q47709428 | Immunohistochemical analysis of p53 protein in uterine sarcomas |
| Q40678047 | Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival |
| Q45988380 | Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery. |
| Q58618983 | Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals |
| Q41226653 | In vitro effects of prolactin and hydrocortisone on 7,12-DMBA-induced mammary tumour and virus-induced sarcoma in the rat |
| Q44943154 | Influence of "nuclear" estrogen receptor content on prognosis of early stage carcinoma of the uterine body. A short-time follow-up. |
| Q74573049 | Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer |
| Q58618991 | Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer |
| Q73161811 | Inherited breast carcinoma--prospective findings in 1,194 women at risk |
| Q53346523 | Intergroup collaboration in ovarian cancer: a giant step forward. |
| Q77974465 | Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions |
| Q35858677 | Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers |
| Q43412797 | Intra-arterial mitomycin C and intravenous bleomycin as induction chemotherapy in advanced head and neck cancer--a phase II study |
| Q36698074 | Intraperitoneal antineoplastic agents in the management of ovarian cancer |
| Q70611043 | Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy |
| Q33603261 | Intraperitoneal treatment and dose-intense therapy in ovarian cancer |
| Q70082168 | Invasive squamous cell carcinoma of the uterine cervix. VIII. Survival and malignancy grading in patients treated by irradiation in Lund 1969-1970 |
| Q41280464 | Involvement of DPP9 in gene fusions in serous ovarian carcinoma |
| Q44017519 | Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? |
| Q81410800 | Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions |
| Q53890877 | Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. |
| Q73121440 | Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study |
| Q79077243 | Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer |
| Q34385830 | Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976-1985. |
| Q59647328 | Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer |
| Q44082262 | Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix |
| Q85709661 | Long-term outcomes after pelvic radiation for early-stage endometrial cancer |
| Q53999204 | Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer. |
| Q54106224 | Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. |
| Q47278984 | Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma |
| Q67488142 | Lymphoid cell distribution as prognostic factor in carcinoma of the uterine cervix |
| Q43905874 | MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival |
| Q71069410 | Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment |
| Q53378990 | Malignant melanoma of the vulva. Evaluation of prognostic factors with emphasis on DNA ploidy in 75 patients. |
| Q53091682 | Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). |
| Q43163115 | Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma |
| Q37947709 | Management of malignant ovarian immature teratoma. Role of adriamycin |
| Q44689165 | Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma |
| Q53419013 | Melphalan with and without doxorubicin in advanced ovarian cancer. |
| Q39730578 | Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions |
| Q46247570 | Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study |
| Q70491233 | Metastasis of a cultured human bladder carcinoma cell line transplanted into nude athymic mice |
| Q40808221 | MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma |
| Q38555569 | MicroRNAs in Ovarian Cancer |
| Q36553567 | Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases |
| Q38858670 | Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties. |
| Q79124323 | Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions |
| Q40816421 | Molecular and biological factors in the pathogenesis of ovarian cancer |
| Q33397152 | Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors |
| Q53257187 | NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. |
| Q84964387 | Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer |
| Q44461877 | Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer |
| Q44886701 | Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? |
| Q53304839 | Netrin‐4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors |
| Q37795682 | New determinates of disease progression and outcome in metastatic ovarian carcinoma |
| Q44803502 | No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients |
| Q77879468 | Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix. Results from a prospective controlled randomized trial |
| Q79432039 | Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma |
| Q53148496 | Nucleoside transporters are widely expressed in ovarian carcinoma effusions. |
| Q53664156 | Occult lymph node metastases in early stage vulvar carcinoma patients. |
| Q71238265 | On heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs. An in vitro study |
| Q38261795 | Ovarian cancer: diagnostic, biological and prognostic aspects |
| Q81737744 | Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors |
| Q74613111 | Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels |
| Q33586710 | Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes |
| Q36136483 | Oxygen tension and vascular density in human cervix carcinoma |
| Q44005165 | P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer |
| Q73793932 | Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer |
| Q53300225 | Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. |
| Q79294683 | Paclitaxel should be included in standard therapy of ovarian carcinoma |
| Q73677797 | Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells |
| Q80836150 | Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study |
| Q43780694 | Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer |
| Q41017555 | Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma |
| Q72890343 | Phase II study of spirogermanium in advanced ovarian malignancy |
| Q50953479 | Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma. |
| Q53867764 | Plasma steroid hormones, cytosol receptors, and thymidine incorporation rate in endometrial carcinoma. |
| Q51549594 | Polarographic measurement of pO2 in cervix carcinoma. |
| Q53109914 | Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer. |
| Q83389106 | Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index |
| Q35262997 | Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort |
| Q43410560 | Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study |
| Q68826223 | Prevalence of mammary carcinoma in patients with gynaecologic cancer |
| Q69290913 | Primary invasive squamous cell carcinoma of the vagina |
| Q36469552 | Primary surgery for ovarian cancer |
| Q35027303 | Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact |
| Q77309890 | Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital |
| Q39694003 | Prognosis of adenocarcinoma of the uterine cervix |
| Q74292297 | Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993 |
| Q37298329 | Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study |
| Q59654389 | Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978–2010) |
| Q43553541 | Prognostic factors in ovarian cancer. |
| Q81604923 | Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? |
| Q39224180 | Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide |
| Q35909215 | Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium |
| Q53328264 | Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. |
| Q43852073 | Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective |
| Q69438471 | Prognostic value of flow cytometrical DNA measurements in stage I-II endometrial carcinoma: correlations with steroid receptor concentration, tumor myometrial invasion, and degree of differentiation |
| Q68114719 | Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis |
| Q69745069 | Prognostic value of steroid receptor concentration and flow cytometrical DNA measurements in stage I-II endometrial carcinoma |
| Q69050110 | Prospective malignancy grading and flow cytometry DNA distribution in biopsy specimens from invasive squamous cell carcinoma of the uterine cervix |
| Q43424741 | Prospective malignancy grading, flow cytometry DNA-measurements and adjuvant chemotherapy for invasive squamous cell carcinoma of the uterine cervix |
| Q50654339 | Prospectively detected cancer in familial breast/ovarian cancer screening. |
| Q38438952 | Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling |
| Q42518544 | Quantitation and localization of cellular retionol-binding protein in squamous-cell carcinomas of the cervix uteri and of the oral cavity |
| Q44052187 | Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma |
| Q72412486 | Radiation Therapy and Surgery in the Treatment of Regional Lymph Nodes in Squamous Cell Carcinoma of the Vulva |
| Q73161844 | Radical radiotherapy versus brachytherapy plus surgery in carcinoma of the cervix 2A and 2B--long-term results from a randomized study 1968-1980 |
| Q44210732 | Radical vulvectomy with warm-knife and open-wound techniques in vulvar malignancies |
| Q71089084 | Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A |
| Q33332312 | Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results |
| Q73793877 | Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument |
| Q46760368 | Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer |
| Q33503971 | Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma |
| Q37725530 | Recurrent fusion transcripts in squamous cell carcinomas of the vulva |
| Q69742626 | Relapse of endometrial carcinoma related to steroid receptor concentration, staging, histologic grading and myometrial invasion |
| Q36713156 | Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer |
| Q38453559 | Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. |
| Q37191988 | SLNB and the importance of micrometastases in vulvar squamous cell carcinoma |
| Q74572329 | Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies |
| Q70681359 | Serum CA 125 level allows early identification of nonresponders during induction chemotherapy |
| Q35080233 | Sex hormone-binding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations |
| Q54677737 | Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. |
| Q70862195 | Some aspects of prophylactic oophorectomy and ovarian carcinoma |
| Q72412491 | Stage I squamous cell carcinoma of the vulva |
| Q33603229 | Surgery during chemotherapy and at relapse of ovarian cancer |
| Q33959852 | Surgery for borderline tumor of the ovary |
| Q34345066 | Surgical management of stage I and II vulvar cancer: the role of the sentinel node biopsy. Review of literature |
| Q88780504 | Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study |
| Q47874846 | Symptoms and referral of women with epithelial ovarian tumors |
| Q51040719 | TGFβ splicing and canonical pathway activation in high-grade serous carcinoma. |
| Q77976580 | TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus |
| Q36696616 | TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival |
| Q73272333 | TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas |
| Q51072014 | TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma. |
| Q34072764 | Tamoxifen in the treatment of recurrent ovarian carcinoma |
| Q77668198 | Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer |
| Q54777583 | The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. |
| Q40011940 | The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers |
| Q40564467 | The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma |
| Q47364530 | The Prognostic Significance of ‘Stage, Tumor Size, Cellular Atypia and DNA Ploidy in Uterine Leiomyosarcoma |
| Q38203092 | The clinical and diagnostic role of microRNAs in ovarian carcinoma |
| Q41747755 | The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions |
| Q67899085 | The close follow-up of immunosuppressed renal recipient women through colposcopy, cervical biopsy and FCM DNA content analysis |
| Q68255109 | The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck |
| Q68990253 | The effect of continuous bleomycin infusion on the growth and cell kinetics of heterotransplanted squamous cell carcinoma of the head and neck |
| Q35684532 | The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study |
| Q74572748 | The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies |
| Q34285178 | The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells |
| Q64944267 | The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas. |
| Q70920029 | The preoperative diagnosis of malignancy of ovarian cysts |
| Q73107925 | The problem of skipped generation and subclinical disease in familial breast-ovarian cancer |
| Q72644277 | The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer |
| Q47327687 | The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma |
| Q34026329 | The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3β and ε are independent prognostic factors for these tumors |
| Q70558825 | The recovery pattern of patients with vulvar melanoma treated by combined surgery and radiation therapy |
| Q81824209 | The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer |
| Q84976702 | The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome |
| Q33633856 | The role of the tumor stroma in ovarian cancer |
| Q73345514 | The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer |
| Q67975860 | Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model |
| Q36115202 | Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status |
| Q58048715 | Three per cent of Norwegian Ovarian Cancers are caused by BRCA1 1675delA or 1135insA |
| Q70167305 | Tranexamic acid for the treatment of advanced ovarian carcinoma |
| Q44234563 | Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis |
| Q70793071 | Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin |
| Q73503229 | Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization |
| Q44550816 | Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993. |
| Q37347191 | Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution |
| Q35695256 | Unsettled questions regarding ovarian cancer |
| Q54523239 | Use of tissue culture in predictive testing of drug sensitivity in human ovarian cancer. Correlation between in vitro results and the response in vivo. |
| Q38643056 | Usefulness of flow cytometric DNA measurements in genital and breast cancers |
| Q50663650 | VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. |
| Q66989522 | Vaginal smear history in patients with invasive cervical carcinoma |
| Q52886435 | Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. |
| Q38868486 | Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival |
| Q53029553 | Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. |
| Q73273747 | [Borderline tumors of the ovary] |
| Q73802550 | [DNA ploidy in epithelial ovarian cancer--an independent prognostic factor] |
| Q73839392 | [Early stage ovarian carcinoma--diagnosis and treatment] |
| Q77962589 | [Endometrial hyperplasia--diagnosis and treatment] |
| Q74343220 | [Epithelial ovarian cancer (advanced stage): consensus conference (1998)] |
| Q74011376 | [Fertility preservation in gynecologic cancer] |
| Q73541208 | [Hormone replacement therapy and cancer] |
| Q81507628 | [Molecular diagnostic techniques in gynaecologic cancer] |
| Q74783805 | [Ovarian cancer and borderline tumors] |
| Q73008107 | [Ovarian cancer screening of high risk groups] |
| Q72121604 | [Preoperative identification of malignancy among women with a pelvic mass] |
| Q57253094 | [Primary treatment of ovarian cancer] |
| Q93922150 | [Screening for cancer] |
| Q73891463 | [Screening for ovarian cancer] |
| Q71400475 | [Staging and differentiated grading are the factors influencing mortality in ovarian cancer] |
| Q50502846 | [Surgery and sentinel node examination in early vulvar cancer] |
| Q70409217 | [Tissue damage after extravasal deposition of doxorubicin] |
| Q71445691 | [Treatment of recurrent cervical cancer with doxorubicin in combination with methotrexate] |
| Q72595428 | [Villous glandular adenocarcinoma of the uterine cervix. A subtype with favourable prognosis?] |
| Q37295492 | miRNA profiling along tumour progression in ovarian carcinoma |
| Q53606953 | p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. |
| Q80600345 | p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas |
| Q53347412 | p53 protein expression in squamous cell carcinoma of the vulva. |
| Q72612972 | β-microglobulin: A tumor marker of gynecologic cancer |
| Q58290999 | β2-Microglobulin in Squamous Cell Carcinomas of the Head and Neck and in Tumours Heterotransplanted into Nude Athymic Mice |
| nb | Claes Göran Tropé | wikipedia |
Search more.